Invitation to the EBAC-accredited Satellite Symposium "Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA".

For more information, please visit the ESC website.

Educational objectives

The educational objectives of the symposium are to:

•    Establish the role of triglycerides as marker for residual cardiovascular risk
•    Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
•    Identify barriers to the implementation of effective, long-term management of ASCVD
•    Provide practical guidance for day to day lipid management in patients with ASCVD

Agenda

15:15 – 15:20    Introduction: A clinical case of a patient with ASCVD and high triglyceride levels - Gabriel Steg, MD - Paris, France

15:20 – 15:30    Understanding the role of triglycerides in the assessment of residual risk - Alberto Zambon, MD, PhD - Padua, Italy

15:30 – 15:40    Managing a patient with residual risk: Applying recent evidence with EPA to practice - Kausik Ray, MD - London, United Kingdom

15:40 – 15:50    Integrating EPA in CV risk reduction strategies: Practical experience and guidance - Azfar Zaman, MD - Newcastle, United Kingdom

15:50 – 15:55    Discussion: 5 burning questions from the audience - All faculty

15:55 – 16:00    The 5 key take home messages - Gabriel Steg, MD - Paris, France

CME Accreditation

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) with 45 minutes effective education time.  Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.

Funding

This symposium is supported by an unrestricted educational grant from Amarin.